[1] FAF-Drugs2 : a free ADME/tox filtering tool to assist drug discovery and chemical biology projects.
Lagorce D, Sperandio O, Galons H, Miteva MA, Villoutreix BO.
BMC Bioinformatics 2008 Sep 24 9:396

[2] OpenBabel package version 2.2.3 - 2009

[3] Pybel: a Python wrapper for the OpenBabel cheminformatics toolkit.
O'Boyle NM, Morley C, Hutchison GR.
Chem Cent J. 2008 Mar 9 2:5

[4] Python Programming Language, version 2.6.4

[5] Computation of octanol-water partition coefficients by guiding an additive model with knowledge.
Cheng T, Zhao Y, Li X, Lin F, Xu Y, Zhang X, Li Y, Wang R, Lai L.
J Chem Inf Model. 2007 Nov-Dec ;47(6):2140-8

[6] Discovery of innovative small molecule therapeutics.
Abou-Gharbia M.
J Med Chem. 2009 Jan 8 ;52(1):2-9.

[7] Assessing drug-likeness: what are we missing?
Vistoli G, Pedretti A, Testa B.
Drug Discov Today. 2008 Apr ;13(7-8):285-294

[8] Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985).
Prentis RA, Lis Y, Walker SR.
Br J Clin Pharmacol. 1988 Mar 25(3):387-96.

[9] Managing the drug discovery/development interface.
Kennedy T.
Drug Discov Today. 1997 Oct 2(10):436-444

[10] In silico prediction of drug properties.
Hutter M.C.
Curr Med Chem. 2009 ;16(2):189-202.

[11] Why drugs fail: a study on side effects in new chemical entities.
Schuster D, Laggner C, Langer T.
Curr Pharm Des. 2005 ;11(27):3545-59.

[12] Drug-Like Properties: Concepts, Structure Design and Methods.From ADME to Toxicity Optimization.
Kerns E.H. and Di L.
Academic Press February 19, 2008 1 edition

[13] Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.
Lipinski C.A.
Adv Drug Deliv Rev 1997 46(1-3): p. 3-26.

[14] Identification and evaluation of molecular properties related to preclinical optimization and clinical fate.
Blake, J.F.
Med Chem. 2005 Nov ;1(6):649-55

[15] Mobyle: a new full web bioinformatics framework.
Néron B, Ménager H, Maufrais C, Joly N, Maupetit J, Letort S, Carrere S, Tuffery P, Letondal C.
Bioinformatics 2009 Nov 15 ;25(22):3005-11

[16] Virtual computational chemistry laboratory--design and description.
Tetko IV, Gasteiger J, Todeschini R, Mauri A, Livingstone D, Ertl P, Palyulin VA, Radchenko EV, Zefirov NS, Makarenko AS, Tanchuk VY, Prokopenko VV.
J Comput Aided Mol Des. 2005 Jun ;19(6):453-63

[17] Description of several chemical structure file formats used by computer programs developed at Molecular Design Limited.
Dalby A, Nourse J, Hounshell W, Gushurst A, Grier D
J Chem Inf and Comp Sc. 1992 32, 244-255

[18] Nonleadlikeness and leadlikeness in biochemical screening.
Rishton GM
Drug Discov Today. 2003 ;8(2):86-96.

[19] Property distribution of drug-related chemical databases.
Oprea TI
J Comput Aided Mol Des 2000 ;14(3):251-264.

[20] Development of a virtual screening method for identification of frequent hitters in compound libraries.
Roche O, Schneider P, Zuegge J, Guba W, Kansy M, Alanine A, Bleicher K, Danel F, Gutknecht EM, Rogers-Evans M, Neidhart W, Stalder H, Dillon M, Sjogren E, Fotouhi N, Gillespie P, Goodnow R, Harris W, Jones P, Taniguchi M, Tsujii S, von der Saal W, Zimmermann G, Schneider G.
J Med Chem 2002 Jan 3 ;45(1):137-42

[21] A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.
McGovern SL, Caselli E, Grigorieff N, Shoichet BK
J Med Chem 2002 45(8):1712-1722

[22] ChemAxon
2010

[23] New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays.
Baell JB and Holloway GA
J Med Chem 2010 53(7):2719-2740

[24] ZINC - A Free Database of Commercially Available Compounds for Virtual Screening.
Irwin JJ and Shoichet BK
J Chem Inf Model 2005 45 (1):177-182

[25] Analysis of the calculated physicochemical properties of respiratory drugs: can we design for inhaled drugs yet?
Ritchie TJ, Luscombe CN, Macdonald SJ
J Chem Inf Model 2009 49(4):1025-32

[26] Generation of a set of simple, interpretable ADMET rules of thumb.
Gleeson MP
J Med Chem 2008 28;51(4):817-34

[27] Leadlikeness and structural diversity of synthetic screening libraries.
Verheij HJ
Mol Divers 2006 10(3):377-88

[28] Can we learn to distinguish between "drug-like" and "nondrug-like" molecules?
Ajay A, Walters WP, Murcko MA
J Med Chem 1998 41(18):3314-24

[29] Drug- and lead-likeness, target class, and molecular diversity analysis of 7.9 million commercially available organic compounds provided by 29 suppliers.
Chuprina A, Lukin O, Demoiseaux R, Buzko A, Shivanyuk A
J Chem Inf Model 2010 26;50(4):470-9

[30] Is There a Difference between Leads and Drugs? A Historical Perspective.
Oprea TI
J Chem Inf Comput Sci 2001 2001, 41 (5), pp 1308-1315

[31] An empirical process for the design of high-throughput screening deck filters.
Pearce BC, Sofia MJ, Good AC, Drexler DM, Stock DA
J Chem Inf Model 2006 46(3):1060-8

[32] Probing the probes: fitness factors for small molecule tools.
Workman P, Collins I
Chem Biol 2006 17(6):561-77

[33] Prediction of drug-likeness.
Walters WP, Murcko MA
Adv Drug Deliv Rev 2002 54(3):255-271

[34] Designing screens: how to make your hits a hit.
Walters WP, Namchuk M
Nat Rev Drug Discov 2003 2(4):259-66

[35] A "rule of three" for fragment-based lead discovery?
Congreve M, Carr R, Murray C, Jhoti H
Drug Discov Today 2003 8(19):876-7

[36] Assessment of the blood-brain barrier in CNS drug discovery.
Jeffrey P, Summerfield S
Neurobiol Dis 2010 37(1):33-7

[38] In silico ADMET traffic lights as a tool for the prioritization of HTS hits.
Lobell M, Hendrix M, Hinzen B, Keldenich J, Meier H, Schmeck C, Schohe-Loop R, Wunberg T, Hillisch A.
ChemMedChem 2006 1(11):1229-36

[39] Escape from flatland: increasing saturation as an approach to improving clinical success.
Lovering F, Bikker J, Humblet C.
J Med Chem. 2009 12;52(21):6752-6

[40] Prediction of drug absorption using multivariate statistics.
Egan WJ, Merz KM Jr, Baldwin JJ.
J Med Chem. 2000 19;43(21):3867-77

[41] Molecular properties that influence the oral bioavailability of drug candidates.
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD.
J Med Chem. 2002 6;45(12):2615-23

[42] PAINS Substructure Filters as SMARTS.
Guha R. 2010

[43] The graphical representation of ADME-related molecule properties for medicinal chemists.
Ritchie TJ, Ertl P, Lewis R.
Drug Discov. Today 2011 6(1-2):65-72

[44] Structural Alert for Toxicity
Blagg J.
Burger's Medicinal Chemistry and Drug Discovery 2010 Book Chapter

[45] ESOL: Estimating Aqueous Solubility Directly from Molecular Structure
John S. Delaney
J. Chem. Inf. Comput. Sci. 2004 44 (3), pp 1000-1005

[46] Calculation of molecular lipophilicity: State-of-the-art and comparison of logP methods on more than 96,000 compounds.
Raimund Mannhold, Gennadiy I. Poda, Claude Ostermann, Igor V. Tetko.
J of Pharm Sci. 2009 Vol 98, Issue 3, pages 861-893

[47] Broad Coverage of Commercially Available Lead-like Screening Space with Fewer than 350,000 Compounds.
Baell JB.
J. Chem. Inf. Model. 2013 53 (1), pp 39–55

[48] Lessons learnt from assembling screening libraries for drug discovery for neglected diseases.
Brenk R, Schipani A, James D, Krasowski A, Gilbert IH, Frearson J, Wyatt PG.
ChemMedChem 2008 3(3):435-44

[49] e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design.
Pihan E, Colliandre L, Guichou JF, Douguet D.
Bioinformatics 2012 1;28(11):1540-1

[50] Rationalizing the chemical space of protein-protein interaction inhibitors.
Sperandio O, Reynès CH, Camproux AC, Villoutreix BO.
Drug Discov Today. 2010 15(5-6):220-9.

[51] Designing focused chemical libraries enriched in protein-protein interaction inhibitors using machine-learning methods.
Reynès C, Host H, Camproux AC, Laconde G, Leroux F, Mazars A, Deprez B, Fahraeus R, Villoutreix BO, Sperandio O.
PLoS Comput Biol. 2010 5;6(3)

[52] Handbook of molecular descriptors.
Todeschini R, Conconni V.
New York: Wiley-VCH 2000

[53] Rules for identifying potentially reactive or promiscuous compounds.
Bruns RF, Watson IA.
J Med Chem. 2012 26;55(22):9763-72

[54] Physiochemical drug properties associated with in vivo toxicological outcomes.
Hughes JD, Blagg J, Price DA, Bailey S, Decrescenzo GA, Devraj RV, Ellsworth E, Fobian YM, Gibbs ME, Gilles RW, Greene N, Huang E, Krieger-Burke T, Loesel J, Wager T, Whiteley L, Zhang Y.
Bioorg Med Chem Lett. 2008 18(17):4872-5

[55] A review of the electrophilic reaction chemistry involved in covalent protein binding relevant to toxicity.
Enoch SJ, Ellison CM, Schultz TW, Cronin MT.
Crit Rev Toxicol. 2011 Oct;41(9):783-802.

[56] A comprehensive listing of bioactivation pathways of organic functional groups.
Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y, O'Donnell JP, Boer J, Harriman SP.
Curr Drug Metab. 2005 Jun;6(3):161-225.

[57] Designing drugs to avoid toxicity.
Smith GF
Prog Med Chem. 2011 50:1-47.

[58] Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS, Aleo MD.
Chem Res Toxicol. 2011 Sep 19;24(9):1345-410

[59] The medicinal chemist's toolbox: an analysis of reactions used in the pursuit of drug candidates.
Roughley SD, Jordan AM.
J Med Chem. 2011 26;54(10):3451-79

[60] Mechanisms of Chemical Carcinogenicity and Mutagenicity A Review with Implications for Predictive Toxicology
Benigni R, Bossa C.
Chem Rev. 2011 Apr 13;111(4):2507-36.

[61] Structure activity relationships in skin sensitization using the murine local lymph node assay.
Ashby J, Basketter DA, Paton D, Kimber I.
Toxicology 1995 Dec 10;103(3):177-94.

[62] Derivation and validation of toxicophores for mutagenicity prediction.
Kazius J, McGuire R, Bursi R.
J Med Chem. 2005 Jan 13;48(1):312-20.

[63] Chemical predictive modelling to improve compound quality.
Cumming JG, Davis AM, Muresan S, Haeberlein M, Chen H.
Nat Rev Drug Discov. 2013 Dec;12(12):948-62.

[64] MLSMR Excluded Functionality Filters
Evotec
2006

[65] 1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase.
Sun Q, Harper TW, Dierks EA, Zhang L, Chang S, Rodrigues AD, Marathe P.
Drug Metab Dispos. 2011 Sep;39(9):1674-9

[66] Design of a General-Purpose European Compound Screening Library for EU-OPENSCREEN.
Horvath D, Lisurek M, Rupp B, Kühne R, Specker E, von Kries J, Rognan D, Andersson CD, Almqvist F, Elofsson M, Enqvist PA, Gustavsson AL, Remez N, Mestres J, Marcou G, Varnek A, Hibert M, Quintana J, Frank R.
ChemMedChem. 2014 Oct;9(10):2309-26

[67] Rational methods for the selection of diverse screening compounds.
Huggins DJ, Venkitaraman AR, Spring DR.
ACS Chem Biol. 2011 Mar 18;6(3):208-17

[68] The use of structure-activity relationship analysis in the food contact notification program.
Bailey AB, Chanderbhan R, Collazo-Braier N, Cheeseman MA, Twaroski ML.
2005 Regul Toxicol Pharmacol.

[69] How Does the Quality of Phospholipidosis Data Influence the Predictivity of Structural Alerts?
Przybylak KR, Alzahrani AR, Cronin MT.
J Chem Inf Model. 2014 25;54(8):2224-32.

[70] FAF-Drugs: free ADME/tox filtering of compound collections.
Miteva MA, Violas S, Montes M, Gomez D, Tuffery P, Villoutreix BO
Nucleic Acids Res. 2006 34(Web Server issue):W738-44.

[71] Promiscuous 2-Aminothiazoles (PrATs): A Frequent Hitting Scaffold.
Devine SM1, Mulcair MD, Debono CO, Leung EW, Nissink JW, Lim SS, Chandrashekaran IR,Vazirani M, Mohanty B, Simpson JS, Baell JB,Scammells PJ, Norton RS, Scanlon MJ.
J Med Chem 2015 DOI: 10.1021/jm501402x

[72] Managing the challenge of chemically reactive metabolites in drug development.
Park BK, Boobis A, Clarke S, Goldring CE, Jones D, Kenna JG, Lambert C, Laverty HG, Naisbitt DJ, Nelson S, Nicoll-Griffith DA, Obach RS, Routledge P, Smith DA, Tweedie DJ, Vermeulen N, Williams DP, Wilson ID, Baillie TA
Nat Rev Drug Discov. 2011 10(4):292-306. doi: 10.1038/nrd3408

[73] OpenEye FILTER
OpenEye Scientific Software
2013

[74] High Throughput Kinetic Profiling Approach for Covalent Binding to Peptides: Application to Skin Sensitization Potency of Michael Acceptor Electrophiles
Roberts DW, Natsch A
Chem. Res. Toxicol. 2009 22,592–603

[75] Extended Functional Groups (EFG): An Efficient Set for Chemical Characterization and Structure-Activity Relationship Studies of Chemical Compounds
Salmina ES, Haider N, Tetko IV
Molecules 2016 21(1), 1

[76] Identification of mechanisms of toxic action for skin sensitisation using a SMARTS pattern based approach.
Enoch SJ, Madden JC, Cronin MT
SAR and QSAR in environmental research 2008 (5-6); 555-78

[77] Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity.
Hill AP, Young RJ.
Drug Discov Today 2010 15(15-16):648-55

[78] FAF-Drugs3: a web server for compound property calculation and chemical library design.
Lagorce D, Sperandio O, Baell JB, Miteva MA, Villoutreix BO.
Nucleic Acids Res. 2015 1;43(W1):W200-7

[79] Quantifying the chemical beauty of drugs.
Bickerton GR, Paolini GV, Besnard J, Muresan S, Hopkins AL.
Nat Chem. 2012 24;4(2):90-8

[80] Using the Golden Triangle to optimize clearance and oral absorption.
Johnson TW, Dress KR, Edwards M.
Bioorg Med Chem Lett. 2009 1;19(19):5560-4